Xylem Inc.

“Xylem operates a structurally sound water technology platform with a widening digital moat, secular demand tailwinds, and improving FCF generation — but trades at 15x EV/EBITDA pricing in margin expansion that has yet to materialize, leaving inadequate margin of safety for new capital. ROIC on a fully-loaded basis (post-Evoqua goodwill) still barely clears cost of capital, management lacks founder-level equity alignment, and the 24–25% EBITDA target has been aspirational for several years. The business warrants patient monitoring; a pullback to $85–95 or demonstrated margin inflection above 22–23% would shift the risk/reward to BUY.”